Crossmark

Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19

Crossref DOI link: https://doi.org/10.1038/s41587-021-01020-4

Published Online: 2021-09-06

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Jihoon W. http://orcid.org/0000-0002-6749-5111
Su, Yapeng http://orcid.org/0000-0002-6305-8467
Baloni, Priyanka http://orcid.org/0000-0002-3382-4941
Chen, Daniel http://orcid.org/0000-0001-6660-6257
Pavlovitch-Bedzyk, Ana Jimena

Yuan, Dan

Duvvuri, Venkata R. http://orcid.org/0000-0001-7356-338X
Ng, Rachel H. http://orcid.org/0000-0003-3692-8524
Choi, Jongchan http://orcid.org/0000-0003-0394-9978
Xie, Jingyi

Zhang, Rongyu

Murray, Kim

Kornilov, Sergey

Smith, Brett

Magis, Andrew T.

Hoon, Dave S. B. http://orcid.org/0000-0003-1915-3683
Hadlock, Jennifer J. http://orcid.org/0000-0001-6103-7606
Goldman, Jason D.

Price, Nathan D. http://orcid.org/0000-0002-4157-0267
Gottardo, Raphael http://orcid.org/0000-0002-3867-0232
Davis, Mark M. http://orcid.org/0000-0001-6868-657X
Hood, Leroy

Greenberg, Philip D. http://orcid.org/0000-0003-3812-647X
Heath, James R. http://orcid.org/0000-0001-5356-4385
License Information

Text and Data Mining valid from 2021-09-06

Version of Record valid from 2021-09-06
More Information

Article History

Received: 1 February 2021

Accepted: 16 July 2021

First Online: 6 September 2021

Competing interests

: J.R.H. is a founder and board member of Isoplexis and PACT Pharma. P.D.G. is on the scientific advisory board of Celsius, Earli, Elpiscience, Immunoscape, Rapt, Metagenomi and Nextech, was a scientific founder of Juno Therapeutics and receives research support from Lonza. R.G. has received consulting income from Juno Therapeutics, Takeda, Infotech Soft, Celgene and Merck, has received research support from Janssen Pharmaceuticals and Juno Therapeutics and declares ownership in CellSpace Biosciences. J.D.G. declared contracted research with Gilead, Lilly and Regeneron and served on an advisory board for Gilead. N.D.P. is CEO of Onegevity Health, a division of Thorne HealthTech, and has stock options in the company. N.D.P. also has stock options in Sera Prognostics and Basepaws for service as a scientific advisor. The remaining authors declare no competing interests.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below